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Abstract
Background: Antibody responses to malaria antigens reflect exposure to parasites, and seroprevalence correlates
with malaria transmission intensity. Antibodies are routinely measured in sera or on dried blood spots but a
non-invasive method would provide extra utility in sampling general populations. Saliva is already in use in the
detection of plasma-derived IgM and IgG to viral infections. In this study, antibodies to Plasmodium falciparum
merozoite antigens were compared between blood and saliva samples from the same individuals in unlinked
surveys conducted in Tanzania and The Gambia.
Methods: In Tanzania, 53 individuals provided paired fingerprick blood and saliva sample using two commercially
available sampling devices. In the Gambia, archived plasma and saliva samples collected from 200 children in the
Farafenni area in a cross-sectional survey were analyzed.
IgG antibodies against P. falciparum antigens, Merozoite Surface Protein-1 (MSP-119) and Apical membrane Antigen
(AMA-1) were measured by ELISA in paired saliva and blood samples from both sites. Antibody levels were
compared as continuous optical density (OD) values and by sero-positivity.
Results: Significant correlations between saliva and plasma antibody levels were seen in Tanzania for both antigens,
AMA-1(r
2 range 0.93 to 0.89, p < 0.001) and MSP-119 (r
2 range 0.93 to 0.75, p < 0.001), with a weaker correlation for
results from The Gambia (r
2range 0.64 to 0.63, p < 0.01). When assessed as seropositivity and compared with plasma,
sensitivity and specificity were good with saliva antibody levels to both AMA-1 and MSP-119 (sensitivity range 64-77%
and specificity range 91-100% & 47-67% and 90-97% respectively) over the different sample sets.
Conclusions: These data demonstrate anti-malarial antibodies can be detected in saliva and correlate strongly with
levels in plasma. This non-invasive relatively simple collection method will be potentially useful for general
population surveys, and particularly in migratory populations or those with infrequent contact with health services
or opposed to blood withdrawal. Further studies will be needed to optimize collection methods, standardize
volumes and content and develop controls.
Background
The strengthening of control efforts has successfully
reduced malaria burden in many countries and reawa-
kened discussions of malaria elimination [1]. Whilst
conjecture remains about whether elimination can be
achieved there is a need to more accurately define
m a l a r i ae x p o s u r ea tt h el o wl e v e l so ft r a n s m i s s i o n ,
which will inevitably be encountered if control measures
succeed [2-4]. More accurate estimates of exposure and
transmission intensity will allow the evaluation of the
impact of control activities and deployment of future
control methods [5].
Parasite rate (PR) and the entomological inoculation
rate (EIR) are the measures widely used to estimate the
transmission intensity for malaria, but these have poor
precision at low transmission levels [6]. It has previously
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any medium, provided the original work is properly cited.been shown that anti-malarial antibodies as age specific
seroconversion rates are an effective tool to assess
malaria endemicity and burden of the disease [5,7-9].
Antibodies can persist for months or years after infec-
tion and, therefore, may have particular utility as a
proxy measure of malaria transmission in low transmis-
sion settings [6].
Samples for both PR and serological estimations are
typically collected as blood by finger prick. However,
drawing blood involves risk of accidental infections
(albeit minor) in resource-poor environments and pre-
s e n t sc h a l l e n g e si nc o m m u nities with blood taboos
[10,11]. One alternative is oral fluid which is a mixture
of IgA-rich saliva and IgG-rich crevicular fluid (a transu-
date of serum expressed at the crevice between teeth
and gums) and is already a substitute of serum samples
in the diagnosis of several pathogens, such as HIV
[12,13]. Commercial saliva-based kits for HIV and illicit
drugs are already available for the detection of human
antibodies for population-based studies [12,14].
Plasmodium DNA has been successfully detected in
saliva samples [15-17] and the additional detection of
antibodies would be a further considerable benefit in
developing rapid, safe and affordable approach to deter-
mine exposure to and infection with Plasmodium falci-
parum. The objective of this study was to evaluate oral
fluid as an alternative to blood collection for the detec-
tion of anti-malarial antibodies. The study reports
results from a prospectively designed collection of
paired plasma and saliva samples in Tanzania and retro-
spective analysis with the same ELISA methodology of
archived plasma and saliva samples from a previously
conducted study in The Gambia [15].
Methods
Study sites and conduct: Tanzania
The study was conducted in July 2009 in rural-central
Tanzania in the villages of Ihanda and Ndurugumi, in
Dodoma Region. In this area, malaria is hypoendemic
with transmission occurring primarily during and imme-
diately after the rainy season, from January to March.
This survey was conducted over a two week period July
2009 and nested within a larger study investigating the
impact of azithromycin for Trachoma treatment on
malariometric indices. The eligible subjects for the study
were parents with a child under five years old and these
were included on a first come first serve basis during
the survey period. The aim was to compare antibody
responses to malaria antigens in saliva collected with
two commercially available saliva collection devices with
antibody responses in plasma from the same individuals.
None of the participants had clinical symptoms of
malaria at the time of the survey. This project received
ethical approval from the Ethical Committees of the
National Institute for Medical Research in Tanzania and
the London School of Hygiene and Tropical Medicine.
Individual informed consent was obtained in Swahili
from the enrolled individuals.
Study site and conduct: The Gambia
In The Gambia, samples were collected in a cross sec-
tional malaria survey in August 2008. The primary aim
of the study was to evaluate the sensitivity of parasite
DNA detection in saliva for diagnosing malaria. Sali-
vary anti-malarial antibodies were measured in a sec-
ond analysis. Following informed consent from either
the parent or guardian of eligible study participants, a
baseline malaria screening of children aged 1 to
15 years was conducted in seven villages around the
Farafenni area. In the Gambia malaria is seasonal,
occurring mainly during the rainy season from July to
November with a peak in September. The study was
jointly reviewed and approved by the Gambian Gov-
ernment-Medical Research Council Laboratories Ethics
Committee and the Programme for Appropriate Tech-
nology in Health (PATH) Research Ethics Committee
(REC) USA.
Sample collection and processing: Tanzania
On completion and signing of the informed consent, saliva
was taken from the parent and then the parent obtained
the sample from the child. Oral fluid was collected from
each participant using two different commercially available
devices, Oracol (Malvern Medical Developments Limited,
Worcester, U.K.) and OraSure-Intercept (OraSure Tech-
nologies, Inc. Bethlehem, PA, US). These devices have pre-
viously been used in the surveillance of viral and bacterial
diseases [10,18-20] and were selected in order to better
understand the efficiency of anti-malarial antibody elution
from human saliva. Oracol was used as previously
described [19,21,22]. Timers were used to be consistent
with the time when collecting the saliva samples in each
individual with a maximum of two minutes per swab
allowed. Samples were initially stored in a cool box prior
to longer-term storage at -20 degrees. For both devices,
the specimens were centrifuged at 1000 g/min for 5 min
[18,19,21], swabs were discarded and the extracted
saliva was pipetted into a 1.5 ml tube and stored at +4°C
until testing.
The blood samples were collected by finger prick on
to Whatman 3 M filter paper, dried with silica gel and
stored at +4°C until testing. The reconstitution of
dried blood spots was conducted as previously
described [8]. Briefly, a 3.5 mm diameter circle was
punched out from a blood spot and reconstituted by
adding 300 μl of the reconstitution buffer made from
PBS/Tween wash solution and 0.1% Azide after over-
night agitation.
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Approximately 1 ml of saliva was collected directly into
sterile 50 ml falcon tube by spitting and concurrently,
250 μl of finger prick blood was collected into EDTA
microtainer tube from each study participant. Samples
were temporarily kept in a cold box in the field and pro-
cessed for storage at the laboratory within 2H of collec-
tion. The plasma fraction was separated from whole blood
by centrifugation at 2,500 rpm while the saliva samples did
not undergo further processing. All samples were stored at
-20°C until serological assays were carried out.
Serological assays
A quantitative enzyme-linked immunosorbent assay
(ELISA) was used to analyse oral fluid and blood sam-
ples to detect IgG antibodies to recombinant blood
stage P. falciparum malaria antigens AMA-1(3D7) and
MSP119 (Wellcome) [23] and conducted as previously
described [6,8]. Briefly, Immulon-4 plates (Nunc) were
coated overnight with 50 μlo f0 . 5μg/ml the antigen.
After blocking 50 μl of each of the samples and stan-
d a r d s( ap o o lo fp o s i t i v es e r af r o mT h eG a m b i a )w e r e
added to duplicate wells; filter paper eluate and plasma
were tested at a final dilution of 1:1,000 for MSP-119 and
1:2,000 for AMA-1. Saliva was used undiluted. The plates
were incubated over night at 4C after which rabbit anti-
human IgG-antibody conjugated to horse-radish peroxi-
dase (Dako) was added at a dilution of 1:5,000. Antibody
responses were detected as optical densities (OD) after
development with o-phenylenediamine (OPD) and read-
ing at a wavelength of 490 nm on a spectrophotometer.
In the absence of known positive and negative saliva sam-
ples serial dilutions of a pool of positive sera control was
included on each ELISA plate together with a non-
immune control pool as negative control.
Statistical analysis
ELISA OD were converted to antibody titres expressed
in Arbitrary Units (AU/ml) using the standard curve
from a pool of hyperendemic sera. Paired t-tests of the
continuous data were conducted and correlation coeffi-
cients calculated. A mixture model was used to define
an arbitrary cut-off for positivity for each sample collec-
tion method [8]. Briefly, the distribution of normalized
OD values was fitted as the sum of two Gaussian distri-
butions (a narrow distribution of sero-negatives and a
broader distribution of sero-positives) using maximum
likelihood methods. The mean OD of the Gaussian cor-
responding to the sero-negative population plus three
standard deviations was used as the cut-off for sero-
positivity. A separate cut off was generated for each
antigen and each sample type (plasma & saliva). Sensi-
tivity analysis was conducted in Stata11 (Statacorp,
Texas).
Results
Matched filter paper or plasma samples and saliva were
available from 53 Tanzanian participants and 200
Gambian participants. Antibody titre results from saliva
compared well with those fromp l a s m ai nb o t hs e t t i n g s
and for all antigens. In Tanzania AMA-1 titres showed
highly significant correlation between the two fluids and
with both oral fluid devices (r²Oracol-fingerprick = 0.89,
r²Orasure-Fingerprick = 0.93, both p < 0.001, figure 1a
&1b, Table 1). Similar results were seen for antibodies
against MSP-119 (r² Oracol-fingerprick = 0.75, r²Ora-
sure-Fingerprick = 0.94, both p < 0.001, figure 1c &1d,
Table 1). Data from The Gambia also showed significant
correlations for all antigens tested though overall corre-
lation coefficients were lower than those observed in
Tanzania (r²AMA-1 = 0.64, r²MSP-119 =0 . 6 3b o t h
p < 0.01). Analysis of antibody titres found that mean
titres were significantly different between plasma and
saliva for all antigens and in both settings except for the
saliva collect via the Oracol sampling device and finger-
prick plasma (Table 1.)
When antibody levels were classified as positive or
negative, prevalences detectable from plasma were sig-
nificantly higher in all but one comparison (Tanzania
MSP1-19 between filter paper and the saliva collected
using Orasure). Using the fingerprick derived plasma
antibody prevalence as the gold standard, sensitivity of
the saliva test is presented in Table 2. Specificity was
uniformly high (> 90%), but sensitivity varied greatly
(46-76%) though the ROC (receiver operating character-
istic curve; the average of sensitivity and specificity) was
consistently 0.72 or above.
Discussion
This study aimed to determine whether anti-malarial
antibodies could be detected in saliva by indirect ELISA
and if the detected antibodies correlated with those
from plasma either collected directly or on filter papers.
Results indicate good correlations between saliva and
serum antibody titres for both antigens tested and
weaker correlations between sero-prevalence. Given that
these data are derived from two studies in different
countries whose only consistency of protocol was the
ELISA assay for antibody detection, the findings suggest
that this innovative and non-invasive sampling method
has some potential for population-based serological sur-
veys for malaria.
Saliva, rich in serum-derived IgM and IgG, represents
a convenient alternative sample collection method to
serum, particularly useful when repeated blood sampling
may not be possible [10]. Saliva collection has several
advantages: it does not involve the usage of sharps, it is
easy to collect and store and could be used to access
communities with blood taboos [24]. It is also likely to
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Figure 1 Scatterplots showing relationship between paired antibody titres from plasma and saliva to P. falciparum merozoite surface
antigen AMA-1 in a)Tanzania and b) The Gambia. In plot a) open red circles represent measures by OraSure and blue circles by OraCol.
Estévez et al. Malaria Journal 2011, 10:104
http://www.malariajournal.com/content/10/1/104
Page 4 of 8be more ethically acceptable for repeat sampling of the
same individual. From a logistical standpoint, the meth-
ods used in this study could be easily transferred to
other laboratories where epidemiological studies are
conducted [20].
However, there are several potential limitations that
need further investigation. Whilst correlations were
good, the overall titres were significantly lower in saliva,
as expected. This difference was most pronounced in
assays conducted in The Gambia and are perhaps a
result of a combination of using directly collected
plasma and a non standardized saliva collection method
(though collection of saliva via spitting is a simple
approach). Plasma levels of hormones and antibodies
are often routinely higher than those in saliva and work
is required to evaluate optimal comparative dilutions
[12]. The sensitivity and thus interpretation of a saliva
based ELISA for detection of trypanosomiasias antibo-
dies was found to be highly dependent on saliva dilution
with a 1:20 dilution providing acceptable result and
those of 1:40 not [25]. Clearly work is needed to stan-
dardise the amount and ‘quality’ of saliva collected. Even
in Tanzania when two similar specific saliva collection
methods were used, Oracol and Orasure, differences in
titres were observed. These probably reflect the way
each of the swabs were used as well as the storage buf-
fer and the material they are made of and the relative
recovery of saliva from the swabs [19,26]. Although both
saliva devices yielded saliva samples suitable for the qua-
litative determination of malaria specific IgG antibody,
these differences would require standardization for
wider use. There is also significant variation in the
amount of saliva produced by individuals [10]. This is
compounded by the further dilution of samples with
buffer a necessary addition to stabilize and preserve sal-
iva during field collection. The identification of a stan-
dard protein against which saliva volume could be
calculated would be useful. Human serum albumin is
one option used in serum and alternatives for saliva
need to be investigated. Similarly, defining a positive
control saliva for use in future assays will be necessary.
The relationship between plasma and saliva antibody
titre and prevalence differed slightly depending on
the target antigen though this relates to the higher
immunogenicity of AMA-1 and the antibody titre it
induces. The greatest discordance between plasma and
saliva titres was observed with the lowest values and this
has been shown when comparing anti-malarial antibo-
dies derived from different sources [8]. Importantly, for
the antigens used in this study which have been most
widely utilized in recent times as markers of exposure,
[27-29], correlations were good. Indeed, combining sero-
positivity to both antigens in this data set increases
overall sensitivity, specificity and ROC to some degree
(for the Oracol device in Tanzania 70.4, 96.2 and 0.83,
respectively and for The Gambia 67.2, 92.5 and 0.8,
respectively). These ROC values reflect only fair accu-
racy but should improve with optimization and using
these antigens together, ideally in a single ELISA to
minimize workload, would likely provide a better mea-
sure of exposure. This study was not designed to com-
pare results between the two study sites. However,
difference in the survey methodologies used, including
t h ed i f f e r e n ta g er a n g eo ft h ei ndividuals recruited, will
account for the some of the variability of the correlation
results observed between the two sites.
This study opens the way for more extensive studies
to assess the potential of human saliva in the detection
of anti-malarial antibodies. Seroprevalence data from
saliva has already been used to describe the immuno-
epidemiology of populations for meningococcal infec-
tion, tetanus and other diseases for many years
[10,11,20,22,30,31]. Moreover, malaria parasite DNA can
also be detected from saliva [15] allowing an assessment
of both exposure and infection from a saliva sample.
Further research in a longitudinal study would help to
determine if anti-malarial saliva antibodies are influ-
enced by food, tobacco or other diseases and could be
extended to study exposure to other malaria species,
such as Plasmodium vivax.
Conclusions
Ultimately, a variety of different diagnostic approaches
are needed to deal with the different epidemiological
and sociological scenarios in malaria. These preliminary
data suggest saliva represents a potential alternative to
blood for the assessment of anti-malarial antibody levels
Table 1 Comparison of antibody titres and prevalence
measured in plasma and saliva against MSP-119 and
AMA-1 P. falciparum merozoite surface antigens
Tanzania (n = 53) The Gambia
(n = 200)
Antigen Plasma Saliva
Oracol
Saliva
Orasure
Plasma Saliva
AMA-1
R
2
0.89 0.93 0.64
Mean response (range) 138
(1-817)
148
(3-902)
108*
(0-871)
317
(0-917)
185*
(45-818)
% positive 47 34 36 36 30
MSP-119
r
2
0.75 0.93 0.63
Mean response (range) 61
(0-769)
62
(0-625)
37*
(0-610)
229
(0-844)
113*
(0-612)
% positive 28 26 15 30 20
* = significant difference between means of titre response in saliva and
plasma using t-test.
ND not done.
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Figure 2 Scatterplots showing relationship between paired antibody titres from plasma and saliva to P. falciparum merozoite surface
antigen MSP-119 in a) Tanzania and b) The Gambia. In plot a) open red circles represent measures by OraSure and blue circles by OraCol.
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standardising the recovery of antibodies are required.
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